Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE In this study, we aimed to investigate the effects of combined treatment with Notch1 signaling blocker DAPT and PI3K/Akt signal blocker LY294002 on metastasis of gastric cancer. 31732769 2020
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE The miR-92b/DAB2IP/PI3K/AKT signalling axis may be a potential therapeutic target to prevent GC progression. 31713929 2020
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE The experimental methods are as follows: (1) The proliferation of HGC-27 cells inhibited by Apatinib and LY294002 was observed by 3-(4,5)-dimethylthiahiazo-(z-y1)-3,5-diphenytetrazoli- umromide (MTT) assay; (2) flow cytometry was adopted to detect the apoptosis of cells after they were treated with drugs and the positive control; (3) different effects of varying concentrations of Apatinib on apoptosis-related genes and proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and cysteine-aspartic acid protease (Caspase) 9, were detected via fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting (WB), and the effects of different concentrations of Apatinib on the protein expressions of PI3K, phosphorylated (p)-PI3K, Akt and p-Akt were detected by Western blotting. 31786865 2020
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE In conclusion, the results of the present study revealed that isoforms S and L of MRPL33, which arise from alternative splicing, exhibited opposing roles in the chemoresponse to epirubicin in gastric cancer via the PI3K/AKT signaling pathway. 30816492 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE AIB1 induces epithelial-mesenchymal transition in gastric cancer via the PI3K/AKT signaling. 31692102 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE Moreover, research on molecular mechanisms indicated that both miRNA-32-5p and shKLF2 downregulated the expression of PTEN and activated the PI3K/AKT signaling to promote the development of gastric cancer. 31497207 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Taken together, LINC02465 is an oncogenic lncRNA that facilitates the tumorigenesis and progression of GC via PI3K/AKT pathway, demonstrating a novel effective therapeutic target and prognostic biomarker for GC patients. 30632400 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Long non-coding RNA PICART1 inhibits cell proliferation by regulating the PI3K/AKT and MAPK/ERK signaling pathways in gastric cancer. 30720166 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Taken together, Rab1A regulates the PI3K-AKT-mTORC1 pathway through the mTORC1 complex consisting of mTORC1, Rheb and Rab1A, and is a promising therapeutic target in GC. 31527621 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Therefore, in the present review, the disorder and function of miRNAs and PTEN/PI3K/Akt signaling in GC are discussed. 30628706 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE Moreover, the PI3K/AKT pathway was found activated in GC. 30302796 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE PI3K/AKT/β-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer. 31816819 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE LOC101928316 molecular mechanism investigates suggested that LOC101928316 can regulate PI3K-Akt-mTOR signaling pathway and change the GC development progression in vivo and in vitro. 31207155 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Through in vitro experiments, we proved that m6A suppression (represented by METTL14 knockdown) promoted GC cell proliferation and invasiveness through activating Wnt and PI3K-Akt signaling, while m6A elevation (represented by FTO knockdown) reversed these phenotypical and molecular changes. m6A may also be involved in interferon signaling and immune responses of GC. 31243897 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE The mechanism analyses further found that SLC25A5-AS1 might act as a competing endogenous RNAs (ceRNA), which was involved in the derepression of PTEN expression, a target gene of miR-19a-3p, and regulate malignant phenotype via PI3K/AKT signalling pathway in GC. 30793479 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 GeneticVariation disease BEFREE In conclusion, the polymorphisms of the two loci, PIK3R3 rs7536272 and mTOR rs2295080, on the PI3K/AKT/mTOR signaling pathway genes are associated with genetic susceptibility to gastric cancer in Chinese population. 29332342 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Our results indicate that adenosine promotes GC cell invasion and metastasis by interacting with A2aR to enhance PI3K-AKT-mTOR pathway signaling. 31339445 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Our findings suggested that CSNK2A1 plays important oncogenic roles in GC invasion via EMT and the PI3K-Akt-mTOR signaling pathway and that CSNK2A1 may serve as a novel prognostic and/or therapeutic target in GC. 31819646 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE These results suggest that LMO4 promotes GC cell invasion and proliferation mainly through PI3K-Akt-mTOR signaling. 31737204 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE MALAT1-miR-183-SIRT1 axis and PI3K/AKT/mTOR pathway may be mechanisms to mediate autophagy in GC. miR-183 may serve as a towardly therapeutic target for GC. 31352788 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE SPP1 was a target gene of miR-340 which could then mediate the PI3K/AKT signaling pathway by targeting SPP1 in GC. 30953349 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE miR-107 promotes growth and metastasis in GC via activation of PI3K-AKT signaling by targeting FAT4, which may be a target for GC treatment. 31297980 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 GeneticVariation disease BEFREE Patients with GC with HP infection were associated with fewer <i>PI3K/AKT</i> pathway genetic mutations and better survival than those without HP infection, especially for EBV-negative and intestinal-type GC. 30796154 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Taken together, our findings identify the MUC16-PI3K/Akt/mTOR-Myc axis as a critical signaling cascade that couples genomic mutations to metabolic reprogramming in GC. 30389134 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions. 30344716 2018